Fetalix was recently featured in the Financial Times article “Portugal welcomes start-ups seeking scale”, which highlighted the country’s growing reputation as a hub for entrepreneurship, innovation, and technology development. The recognition places Fetalix among a group of companies contributing to the emergence of a dynamic ecosystem that supports the creation and growth of innovative ventures.
Over the past decade, Portugal has strengthened its position as an attractive destination for startups, supported by a combination of world-class research institutions, specialised innovation hubs, and a collaborative entrepreneurial environment. Cities such as Lisbon, Porto, and Braga have become important centres for technology and life sciences, fostering the conditions necessary for scientific discoveries to evolve into impactful products and businesses.
Fetalix’s journey began with research conducted at i3S – Institute for Research and Innovation in Health, where the scientific foundations of its regenerative medicine technology were first established. Since then, the company has benefited from the support of innovation-focused organisations, including Startup Braga, whose incubation programme has provided access to a strong network of mentors, entrepreneurs, and industry stakeholders.
Being featured in the Financial Times represents an important milestone for Fetalix and reflects the progress achieved since its foundation. At the same time, it highlights the strength of Portugal’s innovation landscape and its ability to support the development of science-based startups with global ambitions. Fetalix remains committed to advancing regenerative medicine technologies while contributing to the continued growth and international recognition of the Portuguese biotechnology sector.
March 5, 2026
